Stock Events

Stock Events

Synairgen 

$0.000100
16
+$0.00+0%Thursday 20:00

Statistics

Day High
0.0141
Day Low
0.0141
52W High
0.0141
52W Low
0.00001
Volume
10,000
Avg. Volume
0
Mkt Cap
110,266.1
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Sep 24Expected
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2024
Q4 2025
Q2 2026
-0.11
-0.08
-0.04
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.57MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is involved in the development of respiratory treatments, including cystic fibrosis therapies, which could compete with Synairgen's respiratory disease treatments.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences has a broad portfolio of treatments for viral and respiratory diseases, potentially competing with Synairgen's COVID-19 and other respiratory disease treatments.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca has a strong focus on respiratory and immunology, including treatments for asthma and COPD, which could compete with Synairgen's respiratory therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is involved in the development of treatments for respiratory syncytial virus (RSV) and other lung diseases, competing with Synairgen's respiratory focus.
Merck
MRK
Mkt Cap356.01B
Merck & Co. has a diverse drug portfolio that includes treatments for infectious diseases, potentially competing with Synairgen's development of treatments for viral-induced respiratory diseases.
Pfizer
PFE
Mkt Cap158.45B
Pfizer has a broad range of treatments for infectious and respiratory diseases, including COVID-19 vaccines and treatments, competing with Synairgen's respiratory disease focus.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on advanced therapies for serious diseases, including potential treatments for lung diseases, which could compete with Synairgen's respiratory disease treatments.
Novartis
NVS
Mkt Cap268B
Novartis has a strong presence in the respiratory market, including treatments for asthma and COPD, competing with Synairgen's focus on respiratory diseases.
Sanofi
SNY
Mkt Cap95.65B
Sanofi is involved in the development of treatments for respiratory conditions and infectious diseases, potentially competing with Synairgen's focus on respiratory diseases.

About

Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD). Furthermore, Synairgen is developing a LOXL2 inhibitor specifically for idiopathic pulmonary fibrosis (IPF) disease. This LOXL2 inhibitor is being developed through a licensing and collaborative agreement with Pharmaxis Ltd. The company was founded in 2004 and is based in Southampton, United Kingdom.
Show More
CEO
Joseph Tregonning Colliver
Employees
34
Country
United Kingdom
ISIN
GB00B0381Z20
WKN
000A0DK7J

Listings

MU
DE
OMY.MU
STU
DE
OMY.STU
OTC Link
US
SYGGF

0 Comments

Share your thoughts

FAQs

What is Synairgen stock price today?▼
The current price of SYGGF is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Synairgen stock price performance more closely on the chart.
What is Synairgen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Synairgen stocks are traded under the ticker SYGGF.
Is Synairgen stock price growing?▼
SYGGF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Synairgen has showed a -50% decrease.
What is Synairgen market cap?▼
Today Synairgen has the market capitalization of 110,266.1
What is Synairgen revenue for the last year?▼
Synairgen revenue for the last year amounts to 0 USD.
What is Synairgen net income for the last year?▼
SYGGF net income for the last year is -8.57M USD.
How many employees does Synairgen have?▼
As of November 2, 2026, the company has 34 employees.
In which sector is Synairgen located?▼
Synairgen operates in the Health & Wellness sector.
When did Synairgen complete a stock split?▼
Synairgen has not had any recent stock splits.
Where is Synairgen headquartered?▼
Synairgen is headquartered in Southampton, United Kingdom.